Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics and formulations of these conventional therapies available. The biologics—which include the entrenched TNF-alpha inhibitors (i.e., Janssen’s Remicade, AbbVie’s Humira) as well as the more recently launched CAM inhibitor Entyvio (Takeda)—often compete for the smaller, more lucrative moderate to severe market segment. With the potential launch of several additional biologics and small-molecule inhibitors (e.g., Pfizer’s Xeljanz) over the next several years, brand differentiation and understanding of key patient characteristics, including insight into the current clinical profiles of patients being treated with available brands, will be critical for market success.
QUESTIONS ANSWERED
What is the patient share in UC for the biologics (e.g., Humira, Remicade, Entyvio) and other key agents (e.g., Lialda, Pentasa)?
What are the demographic characteristics and clinical profiles of UC patients taking Humira, Remicade, Entyvio, and other key agents?
What are the key risk factors, comorbidities, and co-prescribed therapies by patient segment for UC?
How do patient cohorts for UC compare in care utilization and outcomes (physician visits and other healthcare encounters)?
What insurance type do UC patients have?
What are the reimbursed and out-of-pocket costs for the biologics and other key UC agents? What level of discounting exists between the provider charge and the payer-reimbursed amount, by agent?